Provincial Guidelines for the Clinical Management of Opioid Use Disorder



Keith Ahamad MD

Clinical Assistant Professor, UBC Family and Addiction Medicine, Providence Health Care / Vancouver Coastal Health Research Scientist, BC Centre on Substance Use A Guideline for the Clinical Management of

Opioid Use Disorder

Provincial update: Officially Released Feb 7, 2017







BRITISH COLUMBIA CENTRE for EXCELLEN in HIV/AIDS **Providence** HEALTH CARE How you want to be treated.



Faculty/Presenter Disclosure

- Faculty: Keith Ahamad
- Relationships with commercial interests:
 - Grants/Research Support: CIHR, NIH
 - Speakers Bureau/Honoraria: None
 - Consulting Fees: None
 - Other: BC Centre on Substance Use (MoH),
 Providence Health Care

Disclosure of Commercial Support

- I have NOT received financial support or in-kind support from any commercial interest.
- St Paul's Addiction Medicine Fellowship is funded in part by Goldcorp Corporation
- Potential for conflict(s) of interest:
 None


Mitigating Potential Bias

• No sources of bias

Leading the way in HIV prevention and addiction services


30





Number of deaths and mortality rate attributed to illicit drug use in B.C., 1990 - 2016

755+




Source: Illicit Drug Overdose Deaths in BC, January 1, 2007 to November 30, 2016. Office of the Chief Coroner of BC. Released October 19, 2016.

140 120 100 80 60 40 20 0 Dec Sep Nov Jan Feb Apr Jun ١n Aug Oct Jan Feb Apr Jun Aug Sep Oct Nov Mar May Mar May Ъ 2015 2016 - Average since 2015 Average over past 12 months


Illicit Drug Overdose Deaths by Month, 2015-2016^[2]

Source: Illicit Drug Overdose Deaths in BC, January 1, 2007 to November 30, 2016. Office of the Chief Coroner of BC..


Illicit Drug Overdose Deaths including and excluding Fentanyl, 2007-2016*



Source: Illicit Drug Overdose Deaths in BC, January 1, 2007 to November 30, 2016. Office of the Chief Coroner of BC.




Source: Illicit Drug Overdose Deaths in BC, January 1, 2007 to September 30, 2016. Office of the Chief Coroner of BC. Released October 19, 2016.




Source: Illicit Drug Overdose Deaths in BC, January 1, 2007 to September 30, 2016. Office of the Chief Coroner of BC. Released October 19, 2016.

Reward Pathway




Natural Rewards Elevate Dopamine Levels




Di Chiara et al., Neuroscience, 1999., Fiorino and Phillips, J. Neuroscience, 1997.



Effects of Drugs on Dopamine Release



Di Chiara and Imperato, PNAS, 1988



Evidence for Use of Opioids Long-Term

REVIEW

Annals of Internal Medicine

The Effectiveness and Risks of Long-Term Opioid Therapy for Chronic Pain: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop

Roger Chou, MD; Judith A. Turner, PhD; Emily B. Devine, PharmD, PhD, MBA; Ryan N. Hansen, PharmD, PhD; Sean D. Sullivan, PhD; Ian Blazina, MPH; Tracy Dana, MLS; Christina Bougatsos, MPH; and Richard A. Deyo, MD, MPH

Background: Increases in prescriptions of opioid medications for chronic pain have been accompanied by increases in opioid overdoses, abuse, and other harms and uncertainty about long-term effectiveness.

Purpose: To evaluate evidence on the effectiveness and harms of long-term (>3 months) opioid therapy for chronic pain in adults.

Data Sources: MEDLINE, the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, PsycINFO, and CINAHL (January 2008 through August 2014); relevant studies from a prior review; reference lists; and ClinicalTrials.gov.

Study Selection: Randomized trials and observational studies that involved adults with chronic pain who were prescribed long-term opioid therapy and that evaluated opioid therapy versus placebo, no opioid, or nonopioid therapy; different opioid dosing strategies; or risk mitigation strategies.

Data Extraction: Dual extraction and quality assessment.

Data Synthesis: No study of opioid therapy versus no opioid therapy evaluated long-term (>1 year) outcomes related to pain, function, quality of life, existed abuse, or addiction. Good, and

fair-quality observational studies suggest that opioid therapy for chronic pain is associated with increased risk for overdose, opioid abuse, fractures, myocardial infarction, and markers of sexual dysfunction, although there are few studies for each of these outcomes; for some harms, higher doses are associated with increased risk. Evidence on the effectiveness and harms of different opioid dosing and risk mitigation strategies is limited.

Limitations: Non-English-language articles were excluded, meta-analysis could not be done, and publication bias could not be assessed. No placebo-controlled trials met inclusion criteria, evidence was lacking for many comparisons and outcomes, and observational studies were limited in their ability to address potential confounding.

Conclusion: Evidence is insufficient to determine the effectiveness of long-term opioid therapy for improving chronic pain and function. Evidence supports a dose-dependent risk for serious harms.

Primary Funding Source: Agency for Healthcare Research and Quality.

Ann Intern Med. 2015;162:276-286. doi:10.7326/M14-2559 www.annals.org For author affiliations, see end of text.

NEJM: Opioid Abuse in Chronic Pain –Volkow 2016

The NEW ENGLAND JOURNAL of MEDICINE

REVIEW ARTICLE

Dan L. Longo, M.D., Editor

Opioid Abuse in Chronic Pain — Misconceptions and Mitigation Strategies

Nora D. Volkow, M.D., and A. Thomas McLellan, Ph.D.

HRONIC PAIN NOT CAUSED BY CANCER IS AMONG THE MOST PREVALENT and debilitating medical conditions but also among the most controversial and complex to manage. The urgency of patients' needs, the demonstrated effectiveness of opioid analgesics for the management of acute pain, and the limited therapeutic alternatives for chronic pain have combined to produce an overreliance on opioid medications in the United States, with associated alarming increases in diversion, overdose, and addiction. Given the lack of clinical consensus and research-supported guidance, physicians understandably have questions about whether, when, and how to prescribe opioid analgesics for chronic pain without increasing public health risks. Here, we draw on recent research to address common misconceptions regarding the abuse-related risks of opioid analgesics and highlight strategies to minimize those risks.

From the National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD (N.D.V.); and the Treatment Research Institute, Philadelphia (A.T.M.). Address reprint requests to Dr. Volkow at the National Institute on Drug Abuse, National Institutes of Health, 6001 Executive Blvd., Bethesda, MD 20892, or at nvolkow@nida.nih.gov.

N Engl J Med 2016;374:1253-63. DOI: 10.1056/NEJMra1507771 Copyright © 2016 Massachusetts Medical Society.

SOURCE OF THE OPIOID EPIDEMIC

More than 30% of Americans have some form of acute or chronic pain.^{1,2} Among older adults, the prevalence of chronic pain is more than 40%.² Given the prevalence of chronic pain and its often disabling offects, it is not surprising that opicid

Overdose Death HIV Infections Crime Family Jobs Legal Hospital **Mental Illness**


Science

Inpatient/Outpatient Detox Withdrawal/Taper Psychosocial Treatment OAT Methadone Buprenorphine/Naloxone Mandatory Counselling? Tapers vs. Maintenance

Opiate Addiction

Background

- The province has a guideline for the treatment of opioid use disorder with methadone
- Updated July 2016 to include buprenorphine
- Evidence-based guidance for when to use methadone versus other treatments lacking



Background



Vancouver CoastalHealth



a Guideline for the **Clinical Management of Opioid** Addiction

Published 2015

Released November 2016

Clinical Review & Education

JAMA Clinical Guidelines Synopsis

Clinical Management of Opioid Use Disorder

Beth Dunlap, MD; Adam S. Cifu, MD

GUIDELINE TITLE Guideline for the Clinical Management of **Opioid Addiction**

DEVELOPER Vancouver Coastal Health, Providence Health Care, and Ministry of Health, British Columbia, Canada

RELEASE DATE November 2015

FUNDING SOURCE Funded publicly through governmental grants

TARGET POPULATION Nonpregnant adult patients with opioid use disorder

Summary of the Clinical Problem

Death caused by drug overdose is a major problem in the United States. In 2014, nearly 29 000 people died of opiate overdose.¹ Underlying this trend is a parallel increase in opioid use disorder, de-



fined as a problematic pattern of opioid use leading to clinically significant impairment or dis-

tress. Opioid use disorder contributes to significant mortality, primarily from overdose, as well as morbidity.

Guidelines for treatment of patients addicted to oplates potentially can improve both patient and public health outcomes. Of the estimated 2.5 million people in the United States with opioid addiction,² fewer than half are able to access medication-assisted treatment (MAT), 53.4% of US counties do not have a single prescriber of medications to treat opiold use disorder, and, as of 2014, only 2.2% of US physicians had obtained the necessary waiver to prescribe buprenorphine.³ MAT is an MAT is superior to withdrawal alone. Multiple studies of withdrawal

JAMA

MAJOR RECOMMENDATIONS Opioid withdrawal alone is not recommended for treatment.

- of opioid use disorder in most patients because of increased risks of overdose death and infectious disease, particularly HIV through intravenous drug use, following detoxification (moderate-quality evidence: strong recommendation). In the absence of contraindications, medically supervised
- opioid agonist treatment should be offered to patients. Buprenorphine/naloxone is the preferred first-line treatment. Methadone is an alternative in certain patient populations (high-quality evidence; strong recommendation).
- Psychosocial supports tailored to patient needs may be offered as an adjunct to medical treatment (moderate-quality evidence: conditional recommendation).

Evidence Base

A systematic literature review was the basis of the guideline.⁶ EVIdence was summarized using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria. Strong recommendations were given to use of agonist therapy as first-line treatment on the basis of 7 Cochrane reviews published between 2003 and 2014 with high- to moderate-quality evidence. Study heterogeneity and limited outcome information preduded supporting a single approach to psychosocial interventions and support structures. There have been no meta-analyses of residential treatment programs, many of which provide intensive behavioral therapy along with withdrawal or agonist management while removing the patient from prior environmental triggers for opioid use.

Benefits and Harms

BRITISH COLUMBIA CENTRE ON SUBSTANCE USE

Vancouver CoastalHealth



Opioid Addiction

Clinical Review & Education

JAMA Clinical Guidelines Synopsis Clinical Management of Opioid Use Disorder

Beth Dunlap, MD; Adam S. Cifu, MD

GUIDELINE TITLE GUIDEline for the Clinical Management of Opioid Addiction	MAJOR RECOMMENDATIONS • Opioid withdrawal alone is not recommended for treatment of opioid use disorder in most patients because of increased			
DEVELOPER Vancouver Coastal Health, Providence Health Care, and Ministry of Health, British Columbia, Canada	risks of overdose death and infectious disease, particularly HIV through intravenous drug use, following detoxification (moderate-quality evidence, strong recommendation).			
RELEASE DATE November 2015	 In the absence of contraindications, medically supervised opioid agonist treatment should be offered to patients. 			
FUNDING SOURCE Funded publicly through governmental grants	Buprenorphine/naioxone is the preferred first-line treatment. Methadone is an alternative in certain patient populations (high-quality evidence, strong recommendation). • Psychosocial supports taliored to patient needs may be offered			
TARGET POPULATION Nonpregnant adult patients with opioid use disorder	as an adjunct to medical treatment (moderate-quality evidence, conditional recommendation).			

Summary of the Clinical Problem Evidence Base
Death caused by drug overdose is a major problem in the United A systematic literature review was the basis of the guideline.[®] Evi-States. In 2014, nearly 29 000 people died of oplate overdose.¹ dence was summarized using the Grading of Recommendations Underlying this tend is a parallel increase in oplioid use disorder. de-Assessment, Development, and Evaluation (GRADE) criteria, Strong fined as a problematic pattern of opioid use leading to clinically treatment on the basis of 7 Cochrane reviews published between National and the page 262 significant impairment or dis-2003 and 2014 with high- to moderate-quality evidence. Study tress. Opioid use disorder contributes to significant mortality pri-heterogenetiy and limited outcome information preduded support-mathy form overdose, as well as mortality. Guidelines for treatment of patients addicted to opiates potentially structures. There have been no meta-analyses of residential treat an improve both patient and public health outcomes. Of the estimated ment programs, many of which provide intensive behavioral therapy 2.5 million people in the United States with opioid addiction,² fewer than half are able to access medication-assisted treatment (MAT).53.4% of patient from prior environmental triggers for opioid use.

US counties do not have a single prescriber of medications to treat opi-oid use disorder, and, as of 2014, only 2.2% of US physicians had ob-Benefits and Harms

ned the necessary waiver to prescribe buprenorphine.³ MAT is an MAT is superior to withdrawal alone. Multiple studies of withd

Release date: Feb 7, 2017

A Guideline for the **Clinical Management of**

bioid Use Disorder







Mac	
IC ₁ K	АГЛЕ
Centre McM	laster University

Rank		Type of Evidence
1		Systematic reviews of randomized controlled trials
2	a b	Randomized clinical trials Nonrandomized clinical trials
3	a b	Observational studies with controls Observational studies - no controls
4		Expert consensus

Disclosures

 No member of guideline committee reported direct financial or indirect conflicts of interest

Expert guideline – summary of recommendations

	ummary of Recommendations		Strength of recom- mendation*	Refer to Evidence Summary (pp.)
A	pproaches to avoid			
L	Withdrawal management alone (i.e., detoxification without immediate transition to long-term addiction treatment') is not recommended, since this approach has been associated with elevated rates of relapse, HIV infection and overdose death. This includes rapid (< 1 week) inpatient tapers with methadone or buprenorphine/naloxone.	⊕⊕⊕ Moderate	Strong	17-20
P	ossible first-line treatment options			
2.	Initiate opioid agonist treatment with buprenorphine/naloxone whenever feasible to reduce toxicities and facilitate recovery through safer take-home dosing.	0000 High	Strong	23-25, Table 2
3.	Initiate opioid agonist treatment with methadone when treatment with buprenorphine/naloxone is not preferable (e.g., challenging induction).	0000 High	Strong	21-25, Table 2
4.	If withdrawal management is pursued, for most patients, this can be provided more safely in an outpatient rather than inpatient setting. During withdrawal management, patients should be immediately transitioned to long-term addiction treatment' to assist in preventing relapse and associated harms. See also #9.	⊕⊕⊕ Moderate	Strong	17-20
Å	djunct or alternative treatment options			
5.	For individuals responding poorly to buprenorphine/naloxone, consider transition to methadone.	0000 High	Strong	23-25, Table 2
6.	For individuals responding poorly to methadone, or with successful and sustained response to methadone desiring treatment simplification, consider transition to buprenorphine/naloxone.	⊕⊕⊕ Moderate	Strong	23-25, Table 2
7.	For individuals with a successful and sustained response to agonist treatment desiring medication cessation, consider slow taper (e.g., 12 months). Transition to oral naltrexone could be considered upon cessation of opioids.	⊕⊕⊕ Moderate	Strong	29-31
8.	Psychosocial treatment interventions and supports should be routinely offered in conjunction with pharmacological treatment.	⊕⊕⊕ Moderate	Strong	20-21

Withdrawal management only

- Detox: Inpatient vs. Outpatient
- Intensive Psychosocial Treatment?
- Residential Treatment
- OAT Tapers, Clonidine? Outcomes?





DISCUSSION PAPER UNODC/WHO 2013

Opioid overdose: preventing and reducing opioid overdose mortality





D. Reduced tolerance due to a recent period of abstinence

Recent periods of abstinence (particularly when enforced, such as in a period of incarceration) are a major risk factor for fatal opioid overdose. Substantial evidence from a number of longitudinal studies indicates that the period immediately following release from prison³⁹ and the period immediately following discharge from a detoxification facility pose a significantly elevated risk of overdose.⁴⁰ The main causes of increased overdose mortality among released prisoners who were formerly opiate dependent were the individual's loss of tolerance and erroneous judgement with respect to dosage when returning to opiate use following a period of abstinence.⁴¹

Opioid overdose: preventing and reducing opioid overdose mortality

Safety considerations -Withdrawal management alone

- Detox can potentially be an important first point of contact and a bridge to other treatment options
- However, detox alone associated with:
 - HIV-transmission (MacArthur et al., 2012)
 - High rates of relapse (Strang et al., 2003)
 - Morbidity and Mortality (Luty 2003, Simpson and Friend, 1988)
- THN Training




Residential Treatment


(without maintenance OAT)


- No systematic reviews or meta-analyses
- Signal to some clinical improvement, but much of the literature is outdated (Craddock 1997, Gossop 1999, Hubbard 1989, Simpson 1982)
- Relapse (Smyth et al., 2010)
- No OAT 2 times risk of death (Matthias Pierce 2016)

Maintenance Therapy

- Methadone vs. buprenorphine
- First line?
- Safety profile of medications
- Mandatory counselling
- Take home dosing vs. methadone?
- How long; when and how to taper
- Other evidence-based options







Agonist Treatment | Methadone

MMT vs. no opioid replacement therapy (Mattick et al., Cochrane Review 2009)


- Methadone significantly more effective than nonpharmacological approaches in:
 - Treatment retention
 - Suppression of heroin use



Agonist treatment | Buprenorphine/naloxone

Buprenorphine vs. Methadone Maintenance Therapy (Mattick et al., Cochrane Review 2014)

- At medium/high doses bup/nlx is not markedly different from methadone in terms of treatment retention
- No difference between bup/nlx and MMT in reducing illicit opioid use



Agonist treatment | Buprenorphine/naloxone

Buprenorphine vs. Methadone Maintenance Therapy (Mattick et al., Cochrane Review 2014)

- At medium/high doses bup/nlx is not markedly different treatmer Safety profile?
- No difference between bup/nlx and MMT in reducing illicit opioid use

Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence (Review)

Mattick RP, Breen C, Kimber J, Davoli M





Short communication

Buprenorphine infrequently found in fatal overdose in New York City



E S ^a] ^b] -A R(R(A)

98 unintentional OD b/w June – Oct 2013

2/98 cases tested positive for the bup metabolite Both tested + for 6-MAM, morphine (heroin OD)

hent ighion.

Available online 15 August 2015

Keywords: Buprenorphine Overdose post mortem blood specimens from decedents who had died of an unintentional drug overdoses in 2013. *Methods:* We retrospectively tested consecutive drug overdose cases that occurred from June through October 2013. Cases with available blood specimens were tested for buprenorphine and norbuprenorphine using liquid chromatography-tandem mass spectrometry. Toxicology results were linked to death certificates and case files from New York City Vital Statistics and New York City Office of the Chief Medical Examiner.

Results: Of the 98 unintentional drug overdose fatalities tested, only 2 (2.0%) tested positive for buprenorphine metabolites. All 98 unintentional fatalities involved multiple substances.

Conclusions: Buprenorphine was infrequently found in drug overdose deaths in New York City. Since the safety and efficacy of buprenorphine are well documented, and overdoses resulting from buprenorphine treatment or diversion are very rare, facilitating access to buprenorphine treatment is strongly recommended.

© 2015 Elsevier Ireland Ltd. All rights reserved.


The American Journal on Addictions, 19: 73–88, 2009 Copyright © American Academy of Addiction Psychiatry ISSN: 1055-0496 print / 1521-0391 online DOI: 10.1111/j.1521-0391.2009.00008.x

Indicators of Buprenorphine and Methadone Use and Abuse: What Do We Know?


Jane Carlisle Maxwell, PhD,¹ Elinore F. McCance-Katz, MD, PhD²


¹Addiction Research Institute, The University of Texas at Austin, Austin, Texas ²Department of Psychiatry, University of California San Francisco, San Francisco, California

	All methadone exposures	Methadone deaths	All buprenorphine exposures	Buprenorphine deaths
2000	1,387	26	13	0
2001	1,914	35	21	0
2002	2,696	58	29	0
2003	3,126	44	104	0
2004	3,885	75	318	2
2005	4,256	84	580	1
2006	4,555	108	909	3
2007	5,025	121	1,590	1
2008	4,765	103	2,607	$\left(\begin{array}{c}2\end{array}\right)$




Source: National Poison Data System, American Association of Poison Control Centers. Adapted from Maxwell J, McCance-Katz E. Indicators of buprenorphine and methadone use and abuse: What do we know? The American Journal on Addictions. 2009, 19:73–88





Source: BC Opioid Substitution Treatment System Performance Measures, 2013/2014. Office of the Provincial Health Minister, British Columbia Ministry of Health. Released July 2015.

Reduction in overdose mortality with expanded access to buprenorphine/naloxone (France)




© 2006 by the Infectious Diseases Society of America

Carrieri et al., 2006

Advantages	Disadvantages
Potent opioid agonist	Higher risk of overdose, particularly during treatment initiation
Potentially better treatment retention, particularly for unstable opioid- dependent individuals	Generally requires DWI
May be easier to initiate treatment	More severe side effect profile
Potentially better alternative if buprenorphine was unsuccessful at relieving withdrawal symptoms or associated with severe side effects	More expensive if DWI required
Approved in Canada for primary purpose of pain control (split dose BID or TID dosing); Health Canada exemption required for prescribing	Longer time to achieve therapeutic dose (>35 days)
	Higher potential for adverse drug-drug interactions (e.g. Abx, ARVs)
	Increased risk of cardiac arrhythmias as a result of QTc prolongation

Advantages	Disadvantages
	Potential ↑ risk of drop-out
Reduced risk of injection, diversion, and OD due to naloxone component	May cause precipitated withdrawal if induced inappropriately
Allows for safer take home schedules	May block opioid analgesics used for concurrent pain treatment
Milder side effect profile	Not approved in Canada for the purposes of pain control
Easier to rotate from bup/nlx to methadone	
Flexible take home schedules many contribute to ↑ cost savings and patient autonomy	
Shorter time to achieve therapeutic	

dose (1-3 days)



CBC INVESTIGATES | Fentanyl crisis: Easier access to Suboxone urgently needed, experts say

"We're losing the battle" mom says after ten-fold increase in B.C. fentanyl deaths

By Natalie Clancy, CBC News Posted: Jan 28, 2016 3:00 AM PT | Last Updated: Jan 28, 2016 1:36 PM PT



Elyse "Izzy" Bailey, died Dec 23, 2015 after buying heroin that turned out to be fentanyl. (Debra Bailey)

Equal efficacy Bup = safer

- 1st Line
- Take home dosing schedule?
- Random pill counts
- Random UDS

B.C. College of Physicians and Surgeons lifts 'outdated' restriction on Suboxone to help overdose crisis

Change is expected to expand access to drug that cut overdose deaths by 80% in France

CBC News Posted: Jul 05, 2016 1:29 PM PT | Last Updated: Jul 06, 2016 6:57 PM PT



Suboxone is considered 6 times safer than methadone and stops opiate withdrawal symptoms and heroin cravings. (Getty Images)



About Us Programs

ams For Physicians

Login Contact Us

College of Physicians and Surgeons of British Columbia

Serving the public through excellence and professionalism in medical practice

Suboxone®

Health Canada has released Suboxone® for the substitution treatment of opioid use disorder in adults. Suboxone® combines the partial agonist buprenorphine, a proven therapy for opioid use disorder, and the opiate antagonist naloxone, which limits intravenous misuse and the potential for diversion. The naloxone component of Suboxone® has limited sublingual and oral bioavailability, and is inactive when Suboxone® is taken as prescribed.

A federal authorization is not required to prescribe buprenorphine in British Columbia. Before prescribing more than short-term transitional treatment (no more than one week) physicians should do the following:

- 1. complete a recognized buprenorphine education program (www.suboxonecme.ca)
- prescribe buprenorphine dispensed daily under the supervision of a healthcare professional (daily witnessed ingestion) until the patient has sufficient clinical stability and is able to safely store buprenorphine take-home doses
- 3. be familiar with and follow the *Methadone and Buprenorphine: Clinical Practice Guideline for Opioid Use Disorder* and the professional standard on *Safe Prescribing of Drugs with Potential for Misuse/Diversion*, including:
 - a. reviewing a patient's current medication profile through PharmaNet (e.g. access in office, or via pharmacist communication)
 - b. implementing urine drug testing protocol which involves supervised random testing
 - (Note: buprenorphine may not be detected on standard UDT and may need to be ordered separately)
 - c. documenting discussion of availability and benefits of biopsychosocial support

Physicians are advised to consult more experienced prescribers of buprenorphine when necessary to enhance their knowledge and ensure patient safety during induction or reinduction after missed doses. It is strongly recommended (but no longer mandatory) that buprenorphine prescribers obtain their federal authorization to prescribe methadone for opioid use disorder in order to be able to offer their patients a

Diagnostic Accreditation Program

Drug Programs

Prescription Review Program

Methadone Maintenance Program

Methadone for Opioid Use Disorder

Preceptorship

Suboxone®

Methadone for Analgesia

Methadone for Hospitalists

Temporary

Authorization

Patient Information



College of Physicians and Surgeons of British Columbia

Methadone and Buprenorphine: Clinical Practice Guideline for Opioid Use Disorder

July 2016

4. Carry Privileges

A "carry" refers to patients receiving doses of methadone/buprenorphine to be taken home for selfadministration.

Patients starting MBMT must ingest methadone in the pharmacy under the supervision of a pharmacist (i.e. DWI). Patients who are biopsychosocially stable and who demonstrate appropriate UDT results may be considered for carries. The initial dose of a carry prescription is always witnessed. The decision to initiate carries can only be made by the treating physician. The reasons for granting carry privileges must be documented. Physicians must ensure that carries are safe for both patients and the public. The physician must be satisfied that safe storage of methadone will occur. Unsafe storage and diversion may result in lethal consequences.

The original 2007 manufacturer's product monograph "Serious Warnings and Precautions" section stated, "Suboxone® must be dispensed daily under the supervision of a healthcare professional, for a minimum of two months and until the patient is clinically stable and able to safely store Suboxone® take-home doses." In August 2015, the product monograph black box warning was changed to "Suboxone® must be dispensed daily under the supervision of a healthcare professional, until the patient has sufficient clinical stability and is able to safely store Suboxone® take-home doses." Although the two-month minimum has been removed, the concept of daily supervised dispensing remains, and is dependent upon the patient achieving clinical stability, which could develop sooner, or later than two months.

4. Carry Privileges

A "carry" refers to patients receiving doses of methadone/buprenorphine to be taken home for selfadministration.

Patients starting MBMT must ingest methadone in the pharmacy under the supervision of a pharmacist (i.e. DWI). Patients who are biopsychosocially stable and who demonstrate appropriate UDT results may be considered for carries. The initial dose of a carry prescription is always witnessed. The decision to initiate carries can only be made by the treating physician. The reasons for granting carry privileges must be documented. Physicians must ensure that carries are safe for both patients and the public. The physician must be satisfied that safe storage of methadone will occur. Unsafe storage and diversion may result in lethal consequences.

The original 2007 manufacturer's product monograph "Serious Warnings and Precautions" section stated, "Suboxone® must be dispensed daily under the supervision of a healthcare professional, for a minimum of two months and until the patient is clinically stable and able to safely store Suboxone® take-home doses." In August 2015, the product monograph black box warning was changed to "Suboxone® must be dispensed daily under the supervision of a healthcare professional, until the patient has sufficient clinical stability and is able to safely store Suboxone® take-home doses." Although the two-month minimum has been removed, the concept of daily supervised dispensing remains, and is dependent upon the patient achieving clinical stability, which could develop sooner, or later than two months.

Figure 2. Sample Blister Pack of Medications for Morning



FAMILY MEDICINE

Treating Opioid Addiction With Buprenorphine-Naloxone in Community-Based Primary Care Settings

Ira L. Mintzer, MD¹ Mark Eisenberg, MD² Maria Terra, BA¹ Casey MacVane, MD, MPH² David U. Himmelstein, MD¹ Steffie Woolbandler, MD¹

¹Harvard Medical School/Cambridge Health Alliance, Cambridge, Mass

²MGH-Charlestown HealthCare Center/ Harvard Medical School, Boston, Mass

ABSTRACT

PURPOSE Office-based treatment of opioid addiction with a combination of buprenorphine and naloxone was approved in 2002. Efficacy of this treatment in nonresearch clinical settings has not been studied. We examined the efficacy and practicality of buprenorphine-naloxone treatment in primary care settings.

METHODS We studied a cohort of 99 consecutive patients enrolled in buprenorphine-naloxone treatment for opioid dependence at 2 urban primary care practices: a hospital-based primary care clinic, and a primary care practice in a free-standing neighborhood health center. The primary outcome measure was sobriety at 6 months as judged by the treating physician based on periodic urine drug tests, as well as frequent physical examinations and questioning of the patients about substance use.

RESULTS Fifty-four percent of patients were sober at 6 months. There was no significant correlation between sobriety and site of care, drug of choice, neighborhood poverty level, or dose of buprenorphine-naloxone. Sobriety was correlated with private insurance status, older age, length of treatment, and attending selfhelp meetings.

CONCLUSIONS Opioid-addicted patients can be safely and effectively treated in nonresearch primary care settings with limited on-site resources. Our findings suggest that greater numbers of patients should have access to buprenorphine-naloxone treatment in nonspecialized settings.

Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence (Review)

Amato L, Minozzi S, Davoli M, Vecchi S



- 2011 review
- 35 studies, 4319 participants
- Psychosocial interventions + OAT vs. standard OAT
- No significant benefits retention or treatment outcomes

Tapers?

FACTORS

Research Summary

Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a population-based retrospective cohort study.

NOSYK B, SUN HY, EVANS E, ET AL. ADDICTION 2012;107:1621-9.

Ten years: 1996-2006

Outcome: Sustained successful taper

(no treatment re-entry, opioid-related hospitalization or death for 18 months following last dose) Plan dose reductions to occur bi-weekly or monthly As opposed to more or less frequently

Taper over 12–52 weeks vs < 12 weeks

Taper over a long period

(3 months – 1 year)


Out of 4917 taper attempts,



646 sustained success (13%)

+61% increased odds of success

Prescription Opioid Addiction Treatment Study



Slow release oral morphine

Slow-release oral morphine for maintenance therapy (Ferri et al., Cochrane review 2013)

- Limited evidence in review (3 studies)
- Since this review further support Hammig 2014



Withdrawal Options

Buprenorphine/naloxone taper

Methadone taper

Short-acting opioids

Clonidine and ancillary meds

Encourage:


- Long, slow taper
- Intensive psychosocial followup
- outpatient taper


Ensure:


 take-home naloxone training

Warn:

 risk of OD and death with inpatient taper











Table 1. Clinical management of opioid use disorder



If opioid use continues, consider treatment intensification. > HIGH Where possible, « simplify treatment.

HARM REDUCTION 11-13

7.

8.


Across the treatment intensity spectrum, evidence-based harm reduction should be offered to all, including:

Education re: safer user of sterile syringes/needles and other applicable substance use equipment

9.

- Access to sterile syringes, needles, and other supplies
 Access to Supervised Injection Sites (SIS)
- Take-Home-Naloxone (THN) kits
- 1. Amato et al. 2013
- 2. Gowing et al. 2009
- 3. Gowing et al. 2014
- 4. Amato et al. 2011
- 5. Minozzi et al. 2011
- 6. Mattick et al. 2014
 - Mattick et al. 2009
 - Faggiano et al. 2003

Ferri et al. 2013



BRITISH COLUMBIA CENTRE ON SUBSTANCE USE

Practical Tips: Continuing patients on Bup/Nx

- Collateral from initiating doctor
- Pharmnet!
- Improved retention: 12-16 mg/d
- Know how medication is taken (SL)
- Lower barriers: how long and who to DWI?
 - Benzos, AUD, youth, working, school, psych, homeless
- Random pill counts
- UDS
- RACE line!






WELCOME ABOUT RCCBC F #WALKONTHERURALSIDE RURAL

REAP, Providence Health offer new addictions medicine training

Posted on September 29, 2016 by



The Rural Education Action Plan (REAP) and Providence Health are partnering to offer training in addictions medicine for BC practitioners interested in delivering clinical, inpatient and outpatient care.

This elective is based at St Paul's hospital within the addiction medicine consult team (AMCT) and consists of three (3) academic teams each staffed by one addiction physician. Consultations are requested from all areas of the hospital including the emergency department, medical, surgical and

psychiatric wards. Most patients present to the hospital with medical consequences of substance use.

bweitzel@providencehealth.bc.ca

therapy such as methadone or buprenorphine/naloxone and managing complicated alcohol withdrawal).



ADDICTION MEDICINE FELLOWSHIP

3 streams: Clinical, Nursing, and Social Work

Timeline for 2018-2019 **Clinical** Fellowship:

August 28, 2017	Application process opens	
October 2, 2017	Application deadline	
Nov 6, 2016	Interview period	
to Dec 4, 2017		
December 11, 2017	Acceptance notification	
December 18, 2017	Deadline for acceptance	
July 3, 2018	Fellowship begins	



ADDICTION MEDICINE FELLOWSHIP

3 streams: Clinical, Nursing, and Social Work

Timeline for 2017-2018 Nursing Fellowship:

September 30, 2016	Application process opens	
October 31, 2016	Application deadline	
Nov 15, 2016 to	Interview period	
Jan 16, 2017		
January 30, 2017	Acceptance notification	
February 10, 2017	Deadline for acceptance	
July 3, 2017	Fellowship begins	



ADDICTION MEDICINE FELLOWSHIP

3 streams: Clinical, Nursing, and Social Work

Timeline for 2017-2018 Social Work Fellowship:

December 5, 2016	Application process opens
January 16, 2017	Application deadline
Feb 6 to Mar 3, 2017	Interview period
March 13, 2017	Acceptance notification
March 20, 2017	Deadline for acceptance
July 3, 2017	Fellowship begins



Timeline for 2017-2018 Research Fellowship:

October 31, 2016	Application process opens
December 5, 2016	Application deadline
December 12, 2016	Interview period
January 23, 2017	Acceptance notification
January 30, 2017	Deadline for acceptance
July 3, 2017	Fellowship begins

Training Opportunities

- 2- week sessional payment addiction team at St Paul's
- UBC Enhanced Skills 3-6 months
- Questions? Please email Carmen Rock at <u>crock@cfenet.ubc.ca</u>



Job Opportunities

Vancouver Coastal Health Connections
 Clinic

• Questions? Please email Dr. Dan Pare at **Dan.Pare@vch.ca**



Treatment Guideline Committee





First Nations Health Authority Health through wellness





the northern way of caring





Interior Health



Ministry of Health

Acknowledgements

- Dr. Rolando Barrios
- Ms. Laura Case
- Ms. Anne McNabb
- Mr. Andrew McFarlane
- The BC Centre for Excellence in HIV AIDS
- Ms. Pauline Voon
- Ms. Deborah Graham
- Ms. Emily Wagner
- Mr. James Nakagawa

- Ms. Lianlian Ti
- Ms. Cheyenne Johnson
- Ms. Jessica Jun
- Ms. Maryam Babaei
- Ms. Josey Ross
- Mr. Peter Vann

BRITISH COLUMBIA CENTRE ON SUBSTANCE USE

St. Paul's Hospital 608 - 1081 Burrard Street Vancouver, BC Canada V5Z 1Y6 TEL: 604.806.8477 FAX: 604.806.8464



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS **Providence** HEALTH CARE How you want to be treated.



Indivior[©] Support for buprenorphine

- Buprenorphine CME course
- Additional in-services (upon request)
- RN sessions on induction education
- Patient support materials
- Buprenorphine pearls with an addiction expert

For more information, contact Kathleen MacDonald:

Kathleen.macdonald@indivior.com



Together, we can do this

Strategies to Address British Columbia's Prescription Opioid Crisis

Recommendations from the British Columbia Node of the Canadian Research Initiative on Substance Misuse

November 2015



BRITISH COLUMBIA CENTRE for EXCELLENCI in HIV/AIDS

BRITISH COLUMBIA CENT

Recommendations

In light of the evidence and the unique characteristics of the system of care in BC, a number of steps should immediately be taken to reduce the harms of the pharmaceutical opioid epidemic in British Columbia. These steps include:

STRATEGIES FOR IMPROVED PRESCRIBING PRACTICES

- Make registration for PharmaNet free, and legally require all clinicians with prescribing authority to be registered for PharmaNet and routinely check patients' PharmaNet profiles when writing prescriptions. Exemptions to this requirement could be provided for individuals who practice in areas without Internet access or with other barriers.
- Revise duplicate prescription pads to include a checkbox indicating that the prescribing practitioner has fulfilled his or her legal responsibility to review a patient's PharmaNet record, thereby ruling out duplicate or high-risk co-prescriptions.



- Put in place enforcement measures to ensure that pharmacies are checking PharmaNet to confirm that duplicate prescriptions or other evidence of inappropriate medical care is further brought to the attention of prescribing practitioners and regulatory authorities.
- 4. Change requirements for benzodiazepine prescribing such that benzodiazepines require a prescription on a duplicate prescription pad, in the same way that opioid prescriptions must be written in BC.^{65,67}
- Implement a maximum upper dispense limit for the amount of opioids that a patient may be dispensed at any one time.

STRATEGIES TO IMPROVE OPIOID ADDICTION CARE

6. Dedicate investments into addiction treatment. For instance, buprenorphine/naloxone—a proven treatment for opioid addiction—should be the first line pharmacotherapy option (along with methadone) for opioid addiction, given its superior safety profile with respect to overdose risk compared to methadone?⁴⁻⁷⁷ Improve access to buprenorphine/naloxone by eliminating the requirement that prescribers must have methadone exemptions in order to



prescribe buprenorphine/naloxone. This requirement is unnecessary given the low misuse potential of buprenorphine/naloxone and the low number of buprenorphine/naloxone prescribers the exemption requirement creates?⁸ In lieu of the methadone exemption, prescribers would be

required to complete an online training module on buprenorphine/naloxone prescribing.

- Invest in recovery-oriented care for individuals with opioid addiction.
- Consider comprehensive patient education with regards to risks of poly-substance use and overdose prevention, recognition and response including take home naloxone prescription.^{79,80}
- Increase prescribers' capacity for opioid agonist treatments (e.g., methadone and buprenorphine/ naloxone) via novel collaborative strategies.

LONG-TERM STRATEGIES TO IMPROVE PRESCRIBER KNOWLEDGE

 Invest in BC's medical curricula and continuing medical education for physicians, nurses and other clinicians in addiction diagnosis, treatment and



recovery; pain management including the use of non-opioid analgesics; and safe opioid prescribing, including the potential for serious adverse effects when opioids are co-prescribed with benzodiazepines and other psychotropic medications.^{36,81}

- 12. Coinciding with benzodiazepines transitioning to a duplicate prescription requirement, investment should be made in education for BC prescribers on the known serious harms and clinical limitations of benzodiazepines, as well as the availability of safer alternatives.⁸²
- Support research and educational interventions in emergency departments to enhance safer opioid prescribing practices in this setting.⁸³⁻⁸⁶

If these evidence-based recommendations are enacted quickly, BC has the potential to dramatically reduce fatal overdoses, abuse, addiction and other severe harms related to unsafe opioid prescribing.

Together, we can do this. The time for action is now.

Table 2. Advantages and disadvantages of methadone vs. buprenorphine/naloxone

AD	VANTAGES
METHADONE	BUPRENORPHINE/NALOXONE
 Potentially better treatment retention May be easier to initiate treatment No maximum dose Potentially better alternative if buprenorphine was unsuccessful in relieving withdrawal symptoms, or was associated with severe side effects Approved in Canada for the primary purpose of pain control (as split dose BID or TID dosing; Health Canada exemption to prescribe methadone for analgesia also required) 	 Less risk of overdose due to partial agonist effect and ceiling effect for respiratory depression (in the absence of benzodiazepines or alcohol) Reduced risk of injection, diversion, and overdose due to naloxone component, allowing for safer take-home dosing schedules Milder side effect profile Easier to rotate from buprenorphine/naloxone to methadone More flexible take-home dosing schedules may contribute to increased cost savings and patient autonomy Shorter time to achieve therapeutic dose (1-3 days) Potentially more effective analgesic for treatment of concurrent pain (however, see disadvantages) Fewer drug interactions Milder withdrawal symptoms and easier to discontinue, thus may be a better option for individuals with lower intensity opioid dependence (e.g., oral opioid dependence, infrequent opioid users, infrequent or non- injectors, short history of opioid dependence) and individuals anticipated to be successfully tapered off maintenance treatment in a relatively short period of time

DISADVANTAGES

METHADONE

- Higher risk of overdose, particularly during treatment initiation
- Generally requires daily witnessed ingestion
- More severe side effect profile (e.g., sedation, weight gain, erectile dysfunction)
- More expensive if daily witnessed ingestion required
- Longer time to achieve therapeutic dose (>35 days)
- More difficult to transition to buprenorphine once on methadone
- Higher potential for adverse drug-drug interactions (e.g., antibiotics, antidepressants, antiretrovirals)
- Higher risk of non-medical or other problematic use
- Increased risk of cardiac arrhythmias as a result of QTc prolongation

BUPRENORPHINE/NALOXONE

- Potentially higher risk of drop-out
- May cause precipitated withdrawal if induced inappropriately
- Doses may be suboptimal for individuals with high opioid tolerance
- May block opioid analgesics used for concurrent pain treatment
- Not approved in Canada for the primary purpose of pain control

References

- a) Maremmani I, Gerra G. Buprenorphine-based regimens and methadone for the medical management of opioid dependence: selecting the appropriate drug for treatment. Am J Addict 2010;19:557-68.
- b) Bonhomme J, Shim RS, Gooden R, Tyus D, Rust G. Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options. J Natl Med Assoc 2012;104:342-50.
- c) Centre for Addiction and Mental Health (CAMH). Opioid Dependence Treatment Core Course. Module 2: Treatment Options. Choosing between methadone and buprenorphine maintenance treatment. May 2015

ADDICTION

Impact of treatment for opioid dependence on fatal drugrelated poisoning: a national cohort study in England

Matthias Pierce^{1,2}, Sheila M. Bird³, Matthew Hickman⁴, John Marsden⁵, Graham Dunn², Andrew Jones² & Tim Millar¹

Institute of Brain Behaviour and Mental Health, Faculty of Medical and Human Sciences, University of Manchester, UK,¹ Institute of Population Health, Faculty of Medical and Human Sciences, University of Manchester, UK,² MRC Biostatistics Unit, Cambridge, UK,³ School of Social and Community Medicine, University of Bristol, UK⁴ and Addictions Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK⁵

ABSTRACT

Aims To compare the change in illicit opioid users' risk of fatal drug-related poisoning (DRP) associated with opioid agonist pharmacotherapy (OAP) and psychological support, and investigate the modifying effect of patient characteristics, criminal justice system (CJS) referral and treatment completion. **Design** National data linkage cohort study of the English National Drug Treatment Monitoring System and the Office for National Statistics national mortality database. Data were analysed using survival methods. **Setting** All services in England that provide publicly funded, structured treatment for illicit opioid users. **Participants** Adults treated for opioid dependence during April 2005 to March 2009: 151 983 individuals; 69% male; median age 32.6 with 442 950 person-years of observation. **Measurements** The outcome was fatal DRP occurring during periods in or out of treatment, with adjustment for age, gender, substances used, injecting status and CJS referral. **Findings** There were 1499 DRP deaths [3.4 per 1000 person-years, 95% confidence interval (CI) = 3.2-3.6]. DRP risk increased while patients were not enrolled in any treatment [adjusted hazard ratio (aHR) = 1.73, 95% CI = 1.55-1.92]. Risk when enrolled only in a psychological intervention was double that during OAP (aHR = 2.07, 95% CI = 1.75-2.46). The increased risk when out of treatment was greater for men (aHR = 1.88, 95% CI = 1.67-2.12), illicit drug injectors (aHR = 2.27, 95% CI = 1.97-2.62) and those reporting problematic alcohol use (aHR = 2.37-9.5% CI = 1.92). **Conclusions** Patients when any problematic and problematic alcohol user (aHR = 2.37-9.5% CI = 1.97-2.62)

ADDICTION

Impact of treatment for opioid dependence on fatal drugrelated poisoning: a national cohort study in England

- April 2005 to March 2009: **151,983 individuals**
- There were **<u>1499 DRP</u>**
- risk increased while patients were not enrolled in any treatment (1.73)
- Risk when enrolled only in a psychological intervention was double that during agonist treatment (2.07)
- The increased risk when out of treatment was greater for
 - men
 - illicit drug injectors
 - those reporting problematic alcohol

injecting status and CJS referral. Findings There were 1499 DRP deaths [3.4 per 1000 person-years, 95% confidence interval (CI) = 3.2-3.6]. DRP risk increased while patients were not enrolled in any treatment [adjusted hazard ratio (aHR) = 1.73, 95% CI = 1.55-1.92]. Risk when enrolled only in a psychological intervention was double that during OAP (aHR = 2.07, 95% CI = 1.75-2.46). The increased risk when out of treatment was greater for men (aHR = 1.88, 95% CI = 1.67-2.12), illicit drug injectors (aHR = 2.27, 95% CI = 1.97-2.62) and those reporting problematic alcohol use (aHR = 2.37-9.5% CI = 1.90-2.98). Conclusions Patients when received only psychological support for onicid